-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14

Benzinga·06/01/2026 10:25:45
Listen to the news
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $13.5 to $14.